Mabylon Reports Positive Phase Ia Results in MY006 Peanut Allergy Trial and Initiates Phase Ib Patient Part of the Study; Advances Tree Pollen Allergy Program MY010 toward Clinical Development
- Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trial
- Funding secured for follow-on tree (Fagales) pollen program MY010
Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. Mabylon also announced the initiation of dosing of individuals with peanut allergy in the Phase Ib part of the study. The Company’s antibodies are designed to neutralize disease-relevant allergens, thereby preventing allergic reactions.
EktaH Shows ~50% Reduction in Post-GLP-1 Weight Rebound with Novel Obesity Treatment and Reports Positive Phase I Data
— First-in-class oral mechanism triggers natural satiety hormones, addressing key limitations of GLP-1 therapies
— Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events
EktaH, a clinical-stage biotechnology company, today reported positive preliminary Phase I results and preclinical data for its lead compound NKS-3, a modified fatty acid molecule and the first oral therapy designed to address key limitations of current GLP-1 obesity treatments.
While GLP-1 receptor agonists such as semaglutide and tirzepatide have demonstrated significant weight loss, patients typically regain their baseline weight within 18 months of discontinuing treatment. In addition, current therapies are associated with loss of lean muscle mass and gastrointestinal side effects that drive discontinuation rates above 60%. Equally important, up to one third of obese individuals do not respond to GLP-1 treatments.
C-mo Medical Solutions Receives CE Mark for Its Novel AI-Powered Cough Monitoring Solution
- Regulatory milestone supports broader adoption of C-mo’s privacy-preserving technology in clinical research and medical practice
- Approval covers the biosensor, automated cough monitoring algorithms and software platform
- C-mo allows precise, objective monitoring of cough frequency and intensity across multiple indications
C-mo Medical Solutions, a leading provider of next-generation cough monitoring technology, today announced that it has received CE Mark for C-mo System, its AI-powered cough monitoring solution.
C-mo System is a non-invasive, Class IIa medical device, now CE-marked under EU MDR 2017/745, for monitoring cough in patients across a broad range of indications. The certification covers the biosensor, the automated cough monitoring algorithms and the software platform. Read more…
